Biologic Agents and Alopecia Areata

Katoulis, Alexander; Alevizou, Antigoni; Bozi, Evangelia; Georgala, S.; Mistidou, M.; Kalogeromitros, D.; Stavrianeas, N.

doi:10.1159/000174826

Cited by 18 publications

(14 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We found 11 cases of AA induced by anti-TNF-a therapies in the literature, [5][6][7][8][9][10][11][12][13][14][15] which are summarized in Table 1. There were no differences among genders.…”

Section: Review Of the Literaturementioning

confidence: 99%

Alopecia areata as another immune‐mediated disease developed in patients treated with tumour necrosis factor‐α blocker agents

Ferrán¹,

Calvet

Almirall

et al. 2011

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

Section: Review Of the Literaturementioning

confidence: 99%

Alopecia areata as another immune‐mediated disease developed in patients treated with tumour necrosis factor‐α blocker agents

Ferrán¹,

Calvet

Almirall

et al. 2011

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…[14][15][16][17][18][19][20][21][22][23][24][25][26][27] The pathogenesis of alopecia areata in patients taking anti-TNF-a medications is thought to be caused by the development of autoimmunity as a result of taking the drug. 28,29 The mechanism of the pathogenesis of vandetanib-related alopecia areata remains to be elucidated.…”

Section: Discussionmentioning

confidence: 99%

Vandetanib‐associated alopecia areata in a patient with metastatic medullary thyroid cancer

Jalalat

Cohen

2014

Int J Dermatology

View full text Add to dashboard Cite

“…Not only have studies shown this not to be the case [15], alopecia areata has actually been found to occur during treatment with TNF-α inhibitors. The first case was reported in 2004 with the use of infliximab [16] and since then we have identified 34 cases in the literature, including the TNF-α inhibitors adalimumab [4,[17][18][19][20][21][22][23][24][25][26][27], infliximab [16,23,[28][29][30][31][32], and etanercept (Table 1) [4,22,33,34]. In these cases, alopecia areata was diagnosed by both clinical presentation and histopathology, which was available in the majority of cases.…”

Section: Clinical Subtypes Of Alopecia Seen During Treatment With Tnfmentioning

confidence: 99%

Hair Loss Induced by Tumor Necrosis Factor Alpha Inhibitors

Tosti¹

2014

J Clin Investig Dermatol

View full text Add to dashboard Cite

Background: Alopecia is a possible adverse reaction to Tumor Necrosis Factor alpha (TNF-α) inhibitors. This side effect has become more recognized in recent years through FDA postmarketing surveillance and it description in case reports/case series. Objective:We review the literature and summarize the pathogenesis, clinical presentation, prognosis, and management strategies for TNF-α inhibitor induced alopecia. Methods:We performed a Medline search from January 1998 until August 2013 to identify all cases of alopecia during anti-TNF-α therapy described in the literature. We also reviewed FDA postmarketing data and clinical trials.Results: There were 62 cases of hair loss occurring during therapy with TNF-α inhibitors that we identified during our literature search. The causes of hair loss included alopecia areata, psoriatic alopecia, lichen planopilaris, drug-induced lupus erythematosus, androgenetic alopecia, and telogen effluvium. Alopecia was also a mentioned side effect in three clinical trials and in FDA postmarketing surveillance.Limitations: There are few controlled trials directly studying TNF-α inhibitor induced alopecia and most of our understanding of this clinical condition comes from anecdotal experience.Conclusions: TNF-α inhibitors can cause different types of hair loss including severe alopecia areata and scarring alopecia.

show abstract

Biologic Agents and Alopecia Areata

Cited by 18 publications

References 14 publications

Alopecia areata as another immune‐mediated disease developed in patients treated with tumour necrosis factor‐α blocker agents

Alopecia areata as another immune‐mediated disease developed in patients treated with tumour necrosis factor‐α blocker agents

Vandetanib‐associated alopecia areata in a patient with metastatic medullary thyroid cancer

Hair Loss Induced by Tumor Necrosis Factor Alpha Inhibitors

Contact Info

Product

Resources

About